Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has submitted a routine compliance certificate to BSE for the quarter ended 31st December 2025. The certificate, issued by the company's Registrar and Share Transfer Agent (Beetal Financial & Computer Services Pvt Ltd), confirms that all securities received from Depository Participants for demat (dematerialisation) during the quarter were properly processed — accepted or rejected — and reported back to the depositories. It also confirms that physical share certificates received for demat were mutilated and cancelled, and the depository's name was substituted as the registered owner in the company's member register within the required 15-day timeline. No new shares were issued or any capital action taken — this is purely a procedural filing required every quarter from listed companies. The Managing Director, Yogesh Agrawal, signed the submission dated 6th January 2026.
No impact on shareholders or the stock price. This is a standard quarterly regulatory compliance filing confirming the RTA has handled demat requests correctly, with no change in share capital or ownership structure.